OA11736A - Novel streptococcus antigens. - Google Patents

Novel streptococcus antigens. Download PDF

Info

Publication number: OA11736A
Authority: OA; OAPI
Prior art keywords: bvh; seq; analogs; fragments; polypeptide
Prior art date: 1998-12-23

Application number

OA1200100165A

Other languages

English (en)

Inventor

Bernard R Brodeur

Nathalie Charland

Josee Hamel

Denis Martin

Isabelle Pineau

Clement Rioux

Original Assignee

Shire Biochem Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

1999-12-20

Publication date

2005-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-20 Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc

2005-06-12 Publication of OA11736A publication Critical patent/OA11736A/en

Links

241000194017 Streptococcus Species 0.000 title abstract description 24
108091007433 antigens Proteins 0.000 title abstract description 22
102000036639 antigens Human genes 0.000 title abstract description 22
239000000427 antigen Substances 0.000 title description 19
108091033319 polynucleotide Proteins 0.000 claims abstract description 70
102000040430 polynucleotide Human genes 0.000 claims abstract description 70
239000002157 polynucleotide Substances 0.000 claims abstract description 70
208000015181 infectious disease Diseases 0.000 claims abstract description 19
229960005486 vaccine Drugs 0.000 claims abstract description 19
238000011321 prophylaxis Methods 0.000 claims abstract description 6
208000035143 Bacterial infection Diseases 0.000 claims abstract 3
208000022362 bacterial infectious disease Diseases 0.000 claims abstract 3
241001465754 Metazoa Species 0.000 claims abstract 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 184
102000004196 processed proteins & peptides Human genes 0.000 claims description 183
229920001184 polypeptide Polymers 0.000 claims description 182
239000012634 fragment Substances 0.000 claims description 149
125000003275 alpha amino acid group Chemical group 0.000 claims description 38
239000013598 vector Substances 0.000 claims description 22
238000000034 method Methods 0.000 claims description 20
239000002671 adjuvant Substances 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 12
206010035664 Pneumonia Diseases 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
208000031729 Bacteremia Diseases 0.000 claims description 5
206010033078 Otitis media Diseases 0.000 claims description 5
201000009906 Meningitis Diseases 0.000 claims description 4
238000011282 treatment Methods 0.000 claims description 4
241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 3
241000187654 Nocardia Species 0.000 claims description 2
230000000295 complement effect Effects 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000003248 secreting effect Effects 0.000 claims description 2
230000000069 prophylactic effect Effects 0.000 claims 3
230000001225 therapeutic effect Effects 0.000 claims 3
108090000623 proteins and genes Proteins 0.000 abstract description 127
102000004169 proteins and genes Human genes 0.000 abstract description 69
230000000890 antigenic effect Effects 0.000 abstract description 5
238000002560 therapeutic procedure Methods 0.000 abstract description 4
238000003556 assay Methods 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 67
235000001014 amino acid Nutrition 0.000 description 43
150000001413 amino acids Chemical group 0.000 description 43
241000699670 Mus sp. Species 0.000 description 37
239000000047 product Substances 0.000 description 25
108700026244 Open Reading Frames Proteins 0.000 description 22
108020004414 DNA Proteins 0.000 description 20
239000013612 plasmid Substances 0.000 description 17
108020001507 fusion proteins Proteins 0.000 description 16
102000037865 fusion proteins Human genes 0.000 description 16
241000588724 Escherichia coli Species 0.000 description 15
108091028043 Nucleic acid sequence Proteins 0.000 description 15
210000004027 cell Anatomy 0.000 description 11
101100228799 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gem6 gene Proteins 0.000 description 10
239000002253 acid Substances 0.000 description 10
238000010367 cloning Methods 0.000 description 10
239000003298 DNA probe Substances 0.000 description 8
241001644525 Nastus productus Species 0.000 description 8
230000004927 fusion Effects 0.000 description 8
238000002649 immunization Methods 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
239000012472 biological sample Substances 0.000 description 7
239000000499 gel Substances 0.000 description 7
230000003053 immunization Effects 0.000 description 7
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
238000011725 BALB/c mouse Methods 0.000 description 6
238000012181 QIAquick gel extraction kit Methods 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
239000000523 sample Substances 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
101100167780 Schizosaccharomyces pombe (strain 972 / ATCC 24843) coa2 gene Proteins 0.000 description 5
101100460198 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new14 gene Proteins 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
101100460200 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NEW1 gene Proteins 0.000 description 4
101100172625 Schizosaccharomyces pombe (strain 972 / ATCC 24843) erh1 gene Proteins 0.000 description 4
101100460204 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new4 gene Proteins 0.000 description 4
101100322386 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new8 gene Proteins 0.000 description 4
101100460205 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new9 gene Proteins 0.000 description 4
101100273916 Schizosaccharomyces pombe (strain 972 / ATCC 24843) wip1 gene Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
238000000605 extraction Methods 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
239000013615 primer Substances 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
108020003215 DNA Probes Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
208000035109 Pneumococcal Infections Diseases 0.000 description 3
101100255212 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rsa3 gene Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
239000008272 agar Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000001262 western blot Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
101710109085 Cysteine synthase, chloroplastic/chromoplastic Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
101100390985 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fmc1 gene Proteins 0.000 description 2
101100460203 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new2 gene Proteins 0.000 description 2
101100210181 Schizosaccharomyces pombe (strain 972 / ATCC 24843) vts1 gene Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
241000680505 Streptococcus pneumoniae WU2 Species 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000007479 molecular analysis Methods 0.000 description 2
229940124733 pneumococcal vaccine Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940023143 protein vaccine Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
-1 synthetic multimers) Polymers 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
101150044182 8 gene Proteins 0.000 description 1
101710117373 92 kDa protein Proteins 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101100001669 Emericella variicolor andD gene Proteins 0.000 description 1
241000672609 Escherichia coli BL21 Species 0.000 description 1
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010053317 Hydrophobia Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
101150091684 SPS4 gene Proteins 0.000 description 1
101100460197 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new13 gene Proteins 0.000 description 1
101100460199 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new15 gene Proteins 0.000 description 1
101100221189 Schizosaccharomyces pombe (strain 972 / ATCC 24843) new16 gene Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241000647261 Stellaria umbellata Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000534944 Thia Species 0.000 description 1
102000002933 Thioredoxin Human genes 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003497 anti-pneumococcal effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
108010071644 fragmentin Proteins 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000002523 lectin Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
101150022503 phoR gene Proteins 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229960001973 pneumococcal vaccines Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

OA1200100165A 1998-12-23 1999-12-20 Novel streptococcus antigens. OA11736A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11380098P	1998-12-23	1998-12-23

Publications (1)

Publication Number	Publication Date
OA11736A true OA11736A (en)	2005-06-12

Family

ID=22351610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100165A OA11736A (en)	1998-12-23	1999-12-20	Novel streptococcus antigens.

Country Status (29)

Country	Link
EP (2)	EP2261358B1 (da)
JP (2)	JP4761623B2 (da)
KR (4)	KR101078919B1 (da)
CN (3)	CN100398653C (da)
AP (1)	AP2001002199A0 (da)
AR (1)	AR029322A1 (da)
AT (1)	ATE394489T1 (da)
AU (1)	AU1764900A (da)
BR (1)	BR9916477A (da)
CA (1)	CA2356836C (da)
CL (1)	CL2009002037A1 (da)
CY (3)	CY1108223T1 (da)
CZ (2)	CZ302790B6 (da)
DE (1)	DE69938670D1 (da)
DK (3)	DK2261358T3 (da)
EA (1)	EA007409B1 (da)
ES (3)	ES2400280T3 (da)
HU (1)	HU229664B1 (da)
IL (3)	IL143905A0 (da)
MX (1)	MXPA01006427A (da)
NO (1)	NO330800B1 (da)
NZ (1)	NZ512574A (da)
OA (1)	OA11736A (da)
PL (3)	PL205041B1 (da)
PT (3)	PT1141306E (da)
TR (2)	TR200200633T2 (da)
UY (1)	UY25877A1 (da)
WO (1)	WO2000039299A2 (da)
ZA (1)	ZA200105114B (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE347600T1 (de)	1998-02-20	2006-12-15	Id Biomedical Corp	Gruppe b-streptococcus antigene
EP1801218A3 (en) *	1998-07-27	2007-10-10	Sanofi Pasteur Limited	Nucleic acids and proteins from streptococcus pneumoniae
US20030134407A1 (en)	1998-07-27	2003-07-17	Le Page Richard William Falla	Nucleic acids and proteins from Streptococcus pneumoniae
CA2355364C (en)	1998-12-21	2014-03-18	Medimmune, Inc.	Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US7128918B1 (en)	1998-12-23	2006-10-31	Id Biomedical Corporation	Streptococcus antigens
PL205041B1 (pl) *	1998-12-23	2010-03-31	Id Biomedical Corp	Izolowany polinukleotyd, wektor zawierający izolowany polinukleotyd, komórka gospodarza transfekowana lub transformowana za pomocą tego wektora, sposób wytwarzania polipeptydu kodowanego przez izolowany polinukleotyd, izolowany polipeptyd, chimeryczny polipeptyd, kompozycja do szczepionek zawierająca polipeptyd oraz jej zastosowanie w leczeniu lub zapobieganiu zakażeniu osobnika paciorkowcem
US6866855B2 (en)	2000-06-12	2005-03-15	University Of Saskatchewan	Immunization of dairy cattle with GapC protein against Streptococcus infection
US6833134B2 (en)	2000-06-12	2004-12-21	University Of Saskacthewan	Immunization of dairy cattle with GapC protein against Streptococcus infection
ES2316450T3 (es) *	2000-06-12	2009-04-16	University Of Saskatchewan	Proteina gapc quimerica de streptococcus y su uso en vacunacion y diagnostico.
WO2001098334A2 (en)	2000-06-20	2001-12-27	Shire Biochem Inc.	Streptococcus antigens
US7074415B2 (en)	2000-06-20	2006-07-11	Id Biomedical Corporation	Streptococcus antigens
WO2002079475A2 (en) *	2001-03-30	2002-10-10	Shire Biochem Inc.	Streptococcus pyogenes antigens and corresponding dna fragments
WO2003004650A2 (en) *	2001-07-06	2003-01-16	Shire Biochem Inc.	Group b streptococcus antigens and corresponding dna fragments
GB0130228D0 (en) *	2001-12-18	2002-02-06	Hansa Medica Ab	Protein
US7262024B2 (en)	2001-12-20	2007-08-28	Id Biomedical Corporation	Streptococcus antigens
CN1756843B (zh) *	2003-03-04	2012-03-21	英特塞尔股份公司	化脓链球菌抗原
US7635487B2 (en) *	2003-04-15	2009-12-22	Intercell Ag	S. pneumoniae antigens
JP5792920B2 (ja)	2005-12-22	2015-10-14	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EA200901578A1 (ru)	2007-06-26	2010-08-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CA2694466A1 (en) *	2007-07-23	2009-01-29	Sanofi Pasteur Limited	Immunogenic polypeptides and monoclonal antibodies
KR20110009157A (ko) *	2008-04-16	2011-01-27	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
WO2010036945A2 (en)	2008-09-26	2010-04-01	The Regents Of The University Of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
DK2424562T3 (da)	2009-04-30	2015-12-07	Coley Pharm Group Inc	Pneumokokvaccine og anvendelser deraf
WO2010132833A1 (en)	2009-05-14	2010-11-18	The Regents Of The University Of Michigan	Streptococcus vaccine compositions and methods of using the same
KR101660578B1 (ko)	2009-09-03	2016-09-27	화이자 백신스 엘엘씨	Ｐｃｓｋ９ 백신
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
AU2011336366B2 (en)	2010-12-03	2016-05-12	Sanofi Pasteur Limited	Composition for immunization against Streptococcus pneumoniae
SG10201600435UA (en) *	2011-01-20	2016-02-26	Genocea Biosciences Inc	Vaccines And Compositions Against Streptococcus Pneumoniae
WO2012131504A1 (en)	2011-03-02	2012-10-04	Pfizer Inc.	Pcsk9 vaccine
KR20140033127A (ko)	2011-05-17	2014-03-17	글락소스미스클라인 바이오로지칼즈 에스.에이.	스트렙토코쿠스 뉴모니애에 대한 백신
JP6316755B2 (ja) *	2012-01-05	2018-04-25	ドイチェスクレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓＫｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ	Ｉｄｈ１ｒ１３２ｈ変異陽性がんを治療または診断する手段および方法
CA2894903A1 (en) *	2012-12-14	2014-06-19	Sanofi Pasteur, Ltd.	Methods for assessing immunogenicity
FI3583947T3 (fi)	2014-01-21	2023-10-12	Pfizer	Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
BR112016015835B1 (pt)	2014-01-21	2023-12-26	Pfizer Inc	Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
IL312327B2 (en)	2014-01-21	2026-02-01	Pfizer	Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2930318T3 (es)	2014-02-14	2022-12-09	Pfizer	Conjugados glucoproteicos inmunogénicos
PL3244917T3 (pl)	2015-01-15	2023-07-17	Pfizer Inc.	Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
KR20250058066A (ko)	2015-07-21	2025-04-29	화이자 인코포레이티드	접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Vaccine
US10786561B2 (en)	2015-11-20	2020-09-29	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
BR112019014833A2 (pt)	2017-01-20	2020-04-14	Pfizer	composições imunogênicas para uso em vacinas pneumococais
GB201711635D0 (en)	2017-07-19	2017-08-30	Glaxosmithkline Biologicals Sa	Immunogenic composition
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
US20220016229A1 (en)	2018-12-12	2022-01-20	Pfizer Inc.	Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP7239509B6 (ja)	2019-02-22	2023-03-28	ファイザー・インク	細菌多糖類を精製するための方法
US20220184199A1 (en)	2019-04-10	2022-06-16	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2022542316A (ja)	2019-07-31	2022-09-30	サノフィパスツールインコーポレイテッド	多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
AU2020375214B2 (en)	2019-11-01	2024-02-08	Pfizer Inc.	Escherichia coli compositions and methods thereof
CN115362177A (zh)	2020-02-21	2022-11-18	辉瑞公司	糖类的纯化
KR20220143910A (ko)	2020-02-23	2022-10-25	화이자 인코포레이티드	에스케리키아 콜라이 조성물 및 그의 방법
US20230383324A1 (en)	2020-10-22	2023-11-30	Pfizer Inc.	Methods for purifying bacterial polysaccharides
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
MX2023004912A (es)	2020-10-27	2023-05-16	Pfizer	Composiciones de escherichia coli y metodos de las mismas.
CA3200602A1 (en)	2020-11-04	2022-05-12	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en)	2020-12-23	2025-07-15	Pfizer Inc.	E. coli FimH mutants and uses thereof
WO2022234416A1 (en)	2021-05-03	2022-11-10	Pfizer Inc.	Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en)	2021-05-03	2022-11-10	Pfizer Inc.	Vaccination against bacterial and betacoronavirus infections
CA3221075A1 (en)	2021-05-28	2022-12-01	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP7714690B2 (ja)	2021-05-28	2025-07-29	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
JP2025508749A (ja)	2022-01-13	2025-04-10	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250312433A1 (en)	2022-05-11	2025-10-09	Pfizer Inc.	Process for Producing of Vaccine Formulations With Preservatives
US20260130987A1 (en)	2022-10-19	2026-05-14	Pfizer Inc.	Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en)	2022-11-22	2025-10-01	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120513083A (zh)	2022-12-01	2025-08-19	辉瑞大药厂	肺炎链球菌缀合物疫苗制剂
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en)	2023-03-30	2025-10-16	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252779A1 (es)	2023-04-14	2025-12-22	Pfizer	Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121263203A (zh)	2023-05-19	2026-01-02	葛兰素史克生物有限公司	诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
TW202527906A (zh)	2023-09-14	2025-07-16	美商輝瑞股份有限公司	包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en)	2023-12-23	2025-06-26	Pfizer Inc.	Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en)	2024-03-06	2025-09-12	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh)	2024-03-11	2026-01-16	美商輝瑞股份有限公司	包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219904A1 (en)	2024-04-19	2025-10-23	Pfizer Inc.	Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en)	2024-04-19	2025-10-23	Pfizer Inc.	Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4425437A (en)	1979-11-05	1984-01-10	Genentech, Inc.	Microbial polypeptide expression vehicle
US4431739A (en)	1979-11-05	1984-02-14	Genentech, Inc.	Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en)	1980-04-11	1982-07-06	President And Fellows Of Harvard College	Mature protein synthesis
EP0656014B1 (en) *	1993-03-19	2003-05-14	LINDAHL, Gunnar	Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
CZ394297A3 (cs) *	1995-06-07	1998-04-15	Biochem Vaccines Inc.	Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5928895A (en) *	1996-09-24	1999-07-27	Smithkline Beecham Corporation	IgA Fc binding protein
US5882896A (en) *	1996-09-24	1999-03-16	Smithkline Beecham Corporation	M protein
ATE348887T1 (de) *	1996-10-31	2007-01-15	Human Genome Sciences Inc	Streptococcus pneumoniae antigene und impfstoffe
EP1017828A1 (en) *	1997-09-24	2000-07-12	Regents Of The University Of Minnesota	HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE)
WO1999053940A1 (en) *	1998-04-23	1999-10-28	Uab Research Foundation	PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
EP1144640A3 (en) *	1998-07-27	2001-11-28	Microbial Technics Limited	Nucleic acids and proteins from streptococcus pneumoniae
WO2000006737A2 (en) *	1998-07-27	2000-02-10	Microbial Technics Limited	Streptococcus pneumoniae proteins and nucleic acid molecules
EP1115875A1 (en) *	1998-09-24	2001-07-18	Regents Of The University Of Minnesota	Human complement c3-degrading polypeptide from streptococcus pneumoniae
CA2355364C (en) *	1998-12-21	2014-03-18	Medimmune, Inc.	Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
PL205041B1 (pl) *	1998-12-23	2010-03-31	Id Biomedical Corp	Izolowany polinukleotyd, wektor zawierający izolowany polinukleotyd, komórka gospodarza transfekowana lub transformowana za pomocą tego wektora, sposób wytwarzania polipeptydu kodowanego przez izolowany polinukleotyd, izolowany polipeptyd, chimeryczny polipeptyd, kompozycja do szczepionek zawierająca polipeptyd oraz jej zastosowanie w leczeniu lub zapobieganiu zakażeniu osobnika paciorkowcem

1999
- 1999-12-20 PL PL382437A patent/PL205041B1/pl unknown
- 1999-12-20 CA CA2356836A patent/CA2356836C/en not_active Expired - Fee Related
- 1999-12-20 CZ CZ20100674A patent/CZ302790B6/cs not_active IP Right Cessation
- 1999-12-20 KR KR1020107009285A patent/KR101078919B1/ko not_active Expired - Fee Related
- 1999-12-20 PL PL382438A patent/PL204073B1/pl not_active IP Right Cessation
- 1999-12-20 DK DK10180372.4T patent/DK2261358T3/da active
- 1999-12-20 TR TR2002/00633T patent/TR200200633T2/xx unknown
- 1999-12-20 WO PCT/CA1999/001218 patent/WO2000039299A2/en not_active Ceased
- 1999-12-20 AT AT99960748T patent/ATE394489T1/de active
- 1999-12-20 EP EP10180372.4A patent/EP2261358B1/en not_active Expired - Lifetime
- 1999-12-20 DK DK08155317.4T patent/DK1950302T3/da active
- 1999-12-20 PT PT99960748T patent/PT1141306E/pt unknown
- 1999-12-20 OA OA1200100165A patent/OA11736A/en unknown
- 1999-12-20 TR TR2001/02497T patent/TR200102497T2/xx unknown
- 1999-12-20 HU HU0104774A patent/HU229664B1/hu not_active IP Right Cessation
- 1999-12-20 DK DK99960748T patent/DK1141306T3/da active
- 1999-12-20 ES ES08155317T patent/ES2400280T3/es not_active Expired - Lifetime
- 1999-12-20 CN CNB2005100037492A patent/CN100398653C/zh not_active Expired - Fee Related
- 1999-12-20 CN CNA2007101481600A patent/CN101134775A/zh active Pending
- 1999-12-20 EA EA200100565A patent/EA007409B1/ru not_active IP Right Cessation
- 1999-12-20 DE DE69938670T patent/DE69938670D1/de not_active Expired - Lifetime
- 1999-12-20 MX MXPA01006427A patent/MXPA01006427A/es not_active IP Right Cessation
- 1999-12-20 KR KR1020087008264A patent/KR101170203B1/ko not_active Expired - Fee Related
- 1999-12-20 IL IL14390599A patent/IL143905A0/xx unknown
- 1999-12-20 CZ CZ20012161A patent/CZ303675B6/cs not_active IP Right Cessation
- 1999-12-20 PT PT81553174T patent/PT1950302E/pt unknown
- 1999-12-20 KR KR1020067025282A patent/KR100891398B1/ko not_active Expired - Fee Related
- 1999-12-20 EP EP99960748A patent/EP1141306B1/en not_active Expired - Lifetime
- 1999-12-20 KR KR1020017007963A patent/KR100802198B1/ko not_active Expired - Fee Related
- 1999-12-20 ES ES99960748T patent/ES2306528T3/es not_active Expired - Lifetime
- 1999-12-20 AP APAP/P/2001/002199A patent/AP2001002199A0/en unknown
- 1999-12-20 CN CNB998149047A patent/CN1191362C/zh not_active Expired - Fee Related
- 1999-12-20 NZ NZ512574A patent/NZ512574A/xx not_active IP Right Cessation
- 1999-12-20 BR BR9916477-9A patent/BR9916477A/pt active Search and Examination
- 1999-12-20 PT PT101803724T patent/PT2261358E/pt unknown
- 1999-12-20 JP JP2000591190A patent/JP4761623B2/ja not_active Expired - Fee Related
- 1999-12-20 PL PL349777A patent/PL206576B1/pl unknown
- 1999-12-20 ES ES10180372.4T patent/ES2480417T3/es not_active Expired - Lifetime
- 1999-12-20 AU AU17649/00A patent/AU1764900A/en not_active Abandoned
- 1999-12-23 AR ARP990106746A patent/AR029322A1/es not_active Application Discontinuation
- 1999-12-23 UY UY25877A patent/UY25877A1/es unknown
2001
- 2001-06-19 NO NO20013045A patent/NO330800B1/no not_active IP Right Cessation
- 2001-06-21 ZA ZA200105114A patent/ZA200105114B/en unknown
- 2001-06-21 IL IL143905A patent/IL143905A/en not_active IP Right Cessation
2008
- 2008-07-29 CY CY20081100787T patent/CY1108223T1/el unknown
- 2008-09-21 IL IL194230A patent/IL194230A/en not_active IP Right Cessation
2009
- 2009-11-05 CL CL2009002037A patent/CL2009002037A1/es unknown
2010
- 2010-02-09 JP JP2010026521A patent/JP5039802B2/ja not_active Expired - Fee Related
2012
- 2012-12-27 CY CY20121101268T patent/CY1114722T1/el unknown
2014
- 2014-07-16 CY CY20141100536T patent/CY1115340T1/el unknown

Also Published As

Publication number	Publication date
AP2001002199A0 (en)	2001-09-30
ES2306528T3 (es)	2008-11-01
HUP0104774A3 (en)	2007-10-29
CN1332803A (zh)	2002-01-23
ZA200105114B (en)	2002-11-21
PT1141306E (pt)	2008-07-30
MXPA01006427A (es)	2002-06-04
DE69938670D1 (de)	2008-06-19
DK2261358T3 (da)	2014-07-28
CN101134775A (zh)	2008-03-05
CN100398653C (zh)	2008-07-02
NO20013045D0 (no)	2001-06-19
ATE394489T1 (de)	2008-05-15
HUP0104774A2 (hu)	2002-04-29
WO2000039299A2 (en)	2000-07-06
ES2400280T3 (es)	2013-04-08
PT2261358E (pt)	2014-07-30
ES2480417T3 (es)	2014-07-28
UY25877A1 (es)	2000-08-21
EP2261358A2 (en)	2010-12-15
KR100802198B1 (ko)	2008-02-11
EP2261358B1 (en)	2014-05-14
EA200100565A1 (ru)	2002-04-25
CY1114722T1 (el)	2016-10-05
EP1141306A2 (en)	2001-10-10
JP2010142246A (ja)	2010-07-01
IL143905A0 (en)	2002-04-21
PL349777A1 (en)	2002-09-09
CA2356836C (en)	2011-09-13
EA007409B1 (ru)	2006-10-27
CY1115340T1 (el)	2017-01-04
BR9916477A (pt)	2004-06-22
DK1950302T3 (da)	2013-01-14
KR100891398B1 (ko)	2009-04-02
CZ302790B6 (cs)	2011-11-09
KR101170203B1 (ko)	2012-07-31
CN1654657A (zh)	2005-08-17
PL206576B1 (pl)	2010-08-31
TR200200633T2 (tr)	2002-06-21
JP5039802B2 (ja)	2012-10-03
CA2356836A1 (en)	2000-07-06
DK1141306T3 (da)	2008-08-18
CY1108223T1 (el)	2014-02-12
KR20080036666A (ko)	2008-04-28
HK1118575A1 (en)	2009-02-13
TR200102497T2 (tr)	2002-01-21
CZ303675B6 (cs)	2013-02-27
KR20100063814A (ko)	2010-06-11
CZ20012161A3 (cs)	2001-10-17
EP2261358A3 (en)	2011-02-23
KR20010104693A (ko)	2001-11-26
HU229664B1 (en)	2014-04-28
AU1764900A (en)	2000-07-31
CN1191362C (zh)	2005-03-02
PT1950302E (pt)	2013-01-16
NO330800B1 (no)	2011-07-18
NO20013045L (no)	2001-08-20
EP1141306B1 (en)	2008-05-07
KR101078919B1 (ko)	2011-11-01
WO2000039299A3 (en)	2000-11-02
IL143905A (en)	2011-05-31
CL2009002037A1 (es)	2010-06-25
PL204073B1 (pl)	2009-12-31
JP4761623B2 (ja)	2011-08-31
JP2002533123A (ja)	2002-10-08
NZ512574A (en)	2004-03-26
PL205041B1 (pl)	2010-03-31
AR029322A1 (es)	2003-06-25
IL194230A (en)	2013-12-31
KR20060134227A (ko)	2006-12-27
IL194230A0 (en)	2011-08-01

Publication	Publication Date	Title
EP1141306B1 (en)	2008-05-07	Streptococcus antigens
US8211437B2 (en)	2012-07-03	Streptococcus antigens
US7262024B2 (en)	2007-08-28	Streptococcus antigens
ES2540281T3 (es)	2015-07-09	Antígenos de estreptococos del grupo B
US7074415B2 (en)	2006-07-11	Streptococcus antigens
EP1950302B1 (en)	2012-12-05	Streptococcus antigens
AU2008229967B2 (en)	2012-07-05	Novel streptococcus antigens
AU2010227084B2 (en)	2012-03-29	Group B Streptococcus Antigens
AU2007200130B2 (en)	2007-02-15	Group B Streptococcus Antigens
HK1118575B (en)	2013-04-26	Streptococcus antigens
HK1100752A (en)	2007-09-28	Group b streptococcus antigens